|
Baxter healthcare corporation formerly cook imaging corporation ; formulates remodulin for united therapeutics.
Back to Contents Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Savient Pharmaceuticals, Inc. the "Company" ; on Form 10-K for the year ended December 31, 2004 as filed with the Securities and Exchange Commission on the date hereof the "Report" ; , I, Christopher G. Clement, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to 906 of the Sarbanes-Oxley Act of 2002, that: 1 ; The Report fully complies with the requirements of section 13 a ; or the Securities Exchange Act of 1934; and 2 ; The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. By: s Christopher G. Clement Christopher G. Clement President and Chief Executive Officer March 30, 2005 A signed original of this written statement required by Section 906 has been provided to Savient Pharmaceuticals, Inc. and will be retained by Savient Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
Links to treprostinil Remodulin ; : jap.physiology cgi reprint 99 6 2363 : rxlist cgi generic remodulin cp.
Results & Discussion: Follicle population dynamics in the tissue sections analysed indicated that: true primordial TPM ; follicle numbers of 122 + - 45 accounted for 0.6% of the total number of preantral follicles; early primary follicle numbers of 13, 538 + - 2, 997, accounted for 68.5% of total preantral follicles, whereas the 6, 117 + - 1, 780 of primary follicles, contributed 30.9% of the total preantral follicles. The absence of TPM in the sections analysed from the ovaries of pregnant cows as well as the low number of total preantral follicles overall were also notable. In conclusion, the relative paucity of preantral follicles in the elephant ovary is intriguing and this, along with further evaluation of follicle dynamics in animals of different ages and reproductive status merit further study.
Referenz 903a Neurologie, 11. Auflage ; Steck AJ, Schaeren-Wiemers N., Hartung HP.: Demyelinating inflammatory neuropathies, including Guillain-Barr syndrome. Curr. Opin. Neurol. 11 4, 311-318 ; . Department of Neurology, University of Basel, Switzerland. HYPERLINK "mailto: steck ubaclu bas.ch" steck ubaclu bas.ch The highly complex and multiple mechanisms responsible for the development of demyelinating neuropathies are reviewed, in particular Guillain-Barre syndrome and its variant Miller Fisher syndrome, chronic inflammatory demyelinating neuropathy, multifocal motor neuropathy, anti-myelin-associated glycoprotein neuropathy, as well as experimental models. Recent investigations into the role of auto antibodies against myelin proteins, or glycolipids have given insights into the pathogenesis of demyelinating inflammatory neuropathies. Publication Types: Review Review, Tutorial.
60.3% 95% confidence interval [CI], 55.4%-65.2% that of alcohol dependence, 55.1% 95% CI, 49.7%-60.5% ; . The best-fitting model for the co-occurrence of lifetime nicotine and alcohol dependence included a substantial genetic correlation between both disorders r 0.68; 95% CI, 0.61-0.74 ; and a modest unique environmental correlation r 0.23; 95% CI, 0.14-0.32 and renagel.
The use of both genotypic and phenotypic resistance testing to assist in the choice of subsequent antiretroviral therapy has been used with a favorable response in several clinical trials. While not universally available at this time, these assays should become more available within the next year. Resistance testing is helpful to clinicians and paA I D S.
If you listen again to the conference call you'll see that rb clearly states that fda approval for remodulin is expected only this quarter and that current revenues from remodulin are coming only from europe and renova.
PHA . 301-565-3004 FAX . 301-565-3994 E-mail . pha phassociation Member Services and Pathlight Address Changes . 301-565-3004 PH Helpline daytime, please ; . 1-800-748-7274 ACCESS . 1-888-700-7010 Social Security, insurance, and disability questions ; Accredo's Hotline for Flolan, . 1-866-FIGHT PH Remodulin, Tracleer and Ventavis 1-800-9-FLOLAN 1-877-4VENTAVIS Caremark Remodulin Tracleer Helpline . 1-866-879-2348 Priority Healthcare Remodulin Hotline . 1-877-462-6225 TheraCom's Hotline for Flolan . 1-877-356-5264 Tracleer Access Program . 1-866-228-3546.
Remodulin is an fda approved drug as a continuous subcutaneous infusion or intravenous infusion for those not able to tolerate a subcutaneous infusion ; for the treatment of pulmonary arterial hypertension in patients with nyha class ii-iv symptoms to diminish symptoms associated with exercise and reserpine.
Every 30 minutes for two hours and then every hour if the patient is stable. 4 For non-CIC ICU patients on a maintenance therapy no titration needed ; , vital signs BP, pulse, respiratory rate ; and pulse oximetry monitoring are done every 4 hours or per MD order. For non- CIC ICU patients on maintenance therapy who require a dose titration; vitals every 15 minutes for one hour, every 30 minutes for one hour and then every 4 hours thereafter. NOTE: If the patient is exhibiting adverse reactions overdosing or under-dosing ; or increased respiratory distress, additional monitoring and or an increase in the level of care may be required. The patient may need to transfer to a higher level of care or the Rapid Response Team RRT ; Code Blue Team may need to intervene. These agents must be administered as a continuous infusion via a dedicated central line. In the event of an emergency, Flolan and Remodulin may be temporarily administered via a peripheral line while central access is restored. While in the hospital, these agents must be infused via the hospital's Lifecare 5000 Plum Pumps with the MICRO setting. An additional plum pump needs to be at the patient's bedside in the event of pump failure if Flolan is being administered. If possible, the patient should be placed in a room close to the Nurse's Station so the Nurse can be alerted if the pump alarms. To keep the pump alarms audible, avoid closing the patient's door. If a Flolan patient needs to leave the Nursing Unit for a procedure, a nurse needs to accompany the patient to the Procedural perioperative area so the patient's care can be "handed off" to the Procedural Nurse MD CRNA. The "backup" bag of Flolan additional pump should accompany the patient if they must leave the nursing unit. For Remodulin patients, a nurse-to-nurse communication should occur.
Page 12: The date on "75 Years Ago" should of course be Autumn 1927, not Autumn 1902, and WSC's age should be 52, not 27. Page 28: In the subtitle, for "Fiona Richardson" read "Fiona Reynoldson." Page 36: We apologize for twice mangling the name of Pam Woolliscroft, curator, Spode Museum Trust curator, who assisted with the pitcher article. Page 40, Nine lines up from the last line: the word "second" was mistakenly omitted. The sentence should read: "the eldest son of a duke, marquess or earl is known by his father's second title until he himself succeeds and restasis.
Tion EDTA ; . Am. J. MIed. 19: 798 Nov. ; , 1955. A chelating agent, ethylenediamine tetracetic acid EDTA ; , was used in the treatment of a patient with typical scleroderma, selerodactylia, calcinosis, and arthritis rheumatoid? ; . Treatment was fol.
Remodulin pharmacy
1. Wagenvoort CA. Lung-Biopsy Specimens in the Evaluation of Pulmonary Vascular-Disease. Chest. 1980; 77: 614-625. Wagenvoort CA, Mooi WJ. Plexogenic arteriopathy. In: Biopsy Pathology of the Pulmonary Vasculature. Munro Neville A, Walker F, Gottlieb LS, eds. 1989. Chapman and Hall Medical, London. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, Reid LM, Tuder RM. Pathologic assessment of vasculopathies in pulmonary hypertension. J Coll Cardiol. 2004; 43: 25S-32S. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004; 351: 1425-1436. Chapter 7 Geiger R, Berger RM, Hess J, Bogers AJ, Sharma HS, Mooi WJ. Enhanced expression of vascular endothelial growth factor in pulmonary plexogenic arteriopathy due to congenital heart disease. J Pathol. 2000; 191: 202-207. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med. 1994; 121: 409415. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH. A comparison of continuous intravenous epoprostenol prostacyclin ; with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996; 334: 296-302. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, Diehl JH, Crow J, Long W. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin epoprostenol ; . Results of a randomized trial. Ann Intern Med. 1990; 112: 485-491. Higenbottam T, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol prostacyclin ; . Lancet. 1984; 1: 1046-1047. Wade M, Baker FJ, Roscigno R, DellaMaestra W, Arneson CP, Hunt TL, Lai AA. Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion. J Clin Pharmacol. 2004; 44: 503-509. Laliberte K, Arneson C, Jeffs R, Hunt T, Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium Remodulin ; administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol. 2004; 44: 209-214. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. J Respir Crit Care Med. 2002; 165: 800-804. Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, Tinker A. Differential effects of stable prostacyclin and restoril.
Defined by the Census Bureau. Average annual age-adjusted region-racegender-specific rates were calculated using the method of Lilienfeld and Stolley, with the 2000 United States population as the standard. The method of Chiang was used to estimate the standard error for each age-adjusted rate. RESULTS: Black women demonstrated the highest mortality rates for PAH across all age groups compared to other racial and gender groups. No geographical differences in mortality rates were noted. A bimodal distribution of mortality rates was observed in all racial and gender groups, with higher mortality rates from PAH noted in infants and the elderly. CONCLUSION: Racial disparities in pulmonary hypertension morbidity and mortality are now being recognized, with black women exhibiting substantially increased mortality compared with all other groups. The reasons for this disparity remain unclear. Socioeconomic factors, access to care, co-morbidities and potentially genetic factors specific to race may all impact on PAH outcomes and contribute to the increased mortality seen in black women. CLINICAL IMPLICATIONS: This study gives a new perpective on race and gender as risk factors for increased mortality in Idiopathic Pulmonary Hypertension. Further studies are needed to determine why these differences exist. DISCLOSURE: Kala Davis, None. CLINICAL AND HEMODYNAMIC IMPACT OF SUBCUTANEOUS SQ ; TREPROSTINIL REMODULIN ; IN THE MANAGEMENT OF PULMONARY ARTERIAL HYPERTENSION PAH ; : SINGLE-CENTER EXPERIENCE Francisco J. Soto MD, FCCP * Priyank Jain MBBS, MD James Kleczka MD Ronald Siegel MD Timothy Woods MD David Marks MD Kenneth Presberg MD Medical College of Wisconsin, Milwaukee, WI PURPOSE: Despite the potential benefit of SQ treprostinil for patients with PAH, its use is not widespread in part because of side effects e.g. site pain ; . Furthermore, there is limited literature describing long-term outcomes with this drug. METHODS: We identified 33 patients who have received treatment with SQ Treprostinil since 2002. We report data comparing six-minute walk test 6MWT ; at baseline vs. three months and 12 months of therapy, and brain natriuretic peptide BNP ; during the same period. We also compared changes in hemodynamics and functional class. RESULTS: Mean age was 55 years and most patients were women 82% ; . Most common etiologies of PH were idiopathic PAH 39% ; , collagen vascular disease 24% ; and chronic liver disease 18% ; . Twenty eight patients were naive to prostacyclins and 5 were transitioned from IV prostacyclin. Most of our patients were WHO functional class III and IV. Only two patients 6% ; discontinued treatment because of site pain.6MWT went from 243m at baseline to 301m at 3months n 25, p 0.002 ; and 336m at 12months n 17, p 0.0002 ; . BNP also improved from 240 pg ml at baseline to 155 at 3months n 23, p 0.001 ; and 92 n 17, p 0.02 ; at 12 months. The mean peak Treprostinil dose at 12 months was 44 ng kg min 26-72 range ; . Cardiac Index went from 2.96 at baseline to 3.56 p 0.01 ; after mean treatment duration of 9 months. WHO FC improved from mean of 3 to 2.1 p 0.001 ; . CONCLUSION: Our data support the short and long-term clinical and hemodynamic benefit of SQ treprostinil in patients with PAH. Our success rates are in part related to faster dose escalation and higher treatment doses than those initially recommended. CLINICAL IMPLICATIONS: Our study is somewhat unique given the limited literature describing the long-term effects of this drug. SQ treprostinil is an excellent alternative for severe PAH. It has a safe profile, good tolerance and clinical and hemodynamic benefits. DISCLOSURE: Francisco Soto, None. RELATIONSHIP BETWEEN THE SIX-MINUTE WALK TEST AND CARDIOPULMONARY EXERCISE TEST PARAMETERS IN CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION Sushmita Pamidi MD * Sanjay Mehta MD, FCCP, London Health Sciences Centre, London, ON, Canada PURPOSE: The six-minute walk test 6MWT ; is widely used to measure exercise capacity in pulmonary arterial hypertension PAH ; patients, and serves as the primary end point in many clinical trials. Although the 6MWT has been validated for use in idiopathic PAH, there has been no such validation in PAH patients with scleroderma or other connective tissue diseases CTD ; , where unique co-morbidities exist. In this study, we compare the 6MWT in CTD-PAH patients to the gold standard for exercise evaluation, the cardiopulmonary exercise test CPET ; , and identify baseline predictors of exercise capacity. METHODS: Retrospectively, regression analysis was performed on the 6MWT vs. clinical, hemodynamic, and CPET variables in 28 CTDPAH patients. PAH was diagnosed according to the Venice 2003 criteria. Unencouraged 6MWTs were performed as per previously published guidelines. Treadmill CPETs were performed according to ATS guidelines with breath-breath measurements of oxygen consumption VO2 ; , CO2 produced VCO2 ; , minute ventilation VE ; , and estimation of anaerobic threshold AT ; by monitoring ventilatory equivalents for O2 VE VO2 ; and CO2 VE VCO2 ; . RESULTS: In the 28 CTD-PAH patients, significant correlations were made between the 6MWT and WHO NYHA class r 0.72, p 0.01 ; . In 21 the 28 patients who had echocardiographic right-ventricular systolic pressure RVSP ; measurements, the mean RVSP was 63 -6 mmHg. However, there was no significant correlation r 0.08 ; between the 6MWT and RVSP. For the various CPET parameters, significant correlations were made between the 6MWT and peak VO2 r 0.50, p 0.01 ; , VE VO2 at AT r 0.37, p 0.05 ; , VE VCO2 at AT r 0.40, p 0.03 ; , and peak HR r 0.50, p 0.01 ; . CONCLUSION: 6MWT correlates significantly with PAH severity, as assessed clinically by WHO NYHA criteria, but not with hemodynamic echocardiographic RVSP measurements. 6MWT also correlates well with both cardiac and pulmonary CPET variables. CLINICAL IMPLICATIONS: The 6MWT is recommended for routine clinical follow-up for idiopathic PAH patients. It appears that the 6MWT may be a reliable indicator of exercise capacity in the CTD-PAH population as well. DISCLOSURE: Sushmita Pamidi, None. TRICUSPID ANNULAR PLANE SYSTOLIC EXCURSION PREDICTS MORTALITY IN PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH SCLERODERMA Stephen C. Mathai MD * Paul R. Forfia MD Micah R. Fisher MD Traci Housten-Harris RN, MS Reda E. Girgis MBBS, FCCP Paul M. Hassoun MD Johns Hopkins University, Baltimore, MD PURPOSE: Right ventricular RV ; function, as assessed hemodynamically, has prognostic value in pulmonary arterial hypertension PAH ; . Despite similar hemodynamic characteristics, patients with PAH associated with scleroderma PAH-SSD ; have poorer response to therapy and worse prognosis compared to other forms of PAH. Because rapid clinical deterioration is common in PAH-SSD, non-invasive measures of RV function are particularly important. We examined whether the tricuspid annular plane systolic excursion TAPSE ; is a useful measure of RV function with prognostic significance in PAH-SSD. METHODS: 24 consecutive patients with PAH-SSD underwent right heart catheterization RHC ; , trans-thoracic echocardiogram TTE ; and were followed prospectively. Measures of RV function were assessed on TTE, including TAPSE the total displacement of the tricuspid annulus from end-diastole to end-systole ; . The ability of TAPSE to detect RV systolic dysfunction was tested using ROC curves comparing TAPSE to RV stroke volume index and cardiac index. Time-to-event analyses were performed to examine the relationship between TTE-derived measures of RV function and survival. RESULTS: RHC revealed moderate to severe PAH mean RAP 11 6 mmHg, mean PAP 46 9 mmHg, mean CI 2.2 0.6 L min m2, mean PVR 11 5 Wood units ; . The reproducibility of TAPSE was excellent. 13 of 24 patients died in the follow up period median 16.7 months, range 1.1-25.9 ; . Median survival was 15.1 months. One-year survival estimates based on TAPSE were 86% 95% CI, 33-98% ; for the group with TAPSE 1.8cm and 47% 95% CI, 23-68% ; for the group with TAPSE 1.8cm log-rank P 0.02 ; . In univariable Cox proportional hazards analysis, TAPSE 1.8cm conferred a 7.5-fold increased risk of death compared to those with a TAPSE 1.8cm 95% CI, 1.1-57.7, P 0.05 ; . When included as a continuous variable, for every decrease in TAPSE of 1mm, the risk of death increased by 15% HR 1.15, 95% CI, 1.01-1.31, P 0.04 ; . CONCLUSION: In patients with PAH-SSD, TAPSE is a simple and reproducible assessment of RV function with strong prognostic value. CLINICAL IMPLICATIONS: Future studies of TAPSE in PAH should be conducted to confirm these findings. DISCLOSURE: Stephen Mathai, None.
Inhaled form of remodulin in the pipeline by john martin people prescribed remodulin may soon have another way to take the medication and revlimid.
Patent No. 5, 779, 694 ; Matthew Howard, Marc Mayberg, M. Sean Grady, Rogers Ritter and George Gillies Licensed to Stereotaxis, Inc. One of the most important inventions resulting from UVA research is an apparatus for delivery of therapeutic agents to hard-to-reach portions of the body. UVA researchers have developed a system whereby a small magnetic object dragging an encapsulated therapeutic agent is moved through the body by an intricate array of external magnets. This system is ideal for the delivery of drugs to specific regions of the brain. This stereotactic system resembles a basic MRI machine. This figure illustrates a magnetic drive system using superconductive drive magnets and remodulin.
|
